205 related articles for article (PubMed ID: 38186570)
1. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S
Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570
[TBL] [Abstract][Full Text] [Related]
2. Performance of a PLK1-based immune risk model for prognosis and treatment response prediction in breast cancer.
Chen Y; You Y; Wu Q; Wu J; Lin S; Sun Y; Cui Z
Cancer Med; 2023 May; 12(9):11020-11039. PubMed ID: 36951624
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
4. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
6. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
[TBL] [Abstract][Full Text] [Related]
7. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
[TBL] [Abstract][Full Text] [Related]
8. Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients.
Shen HY; Xu JL; Zhu Z; Xu HP; Liang MX; Xu D; Chen WQ; Tang JH; Fang Z; Zhang J
Neoplasia; 2023 Nov; 45():100942. PubMed ID: 37839160
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract][Full Text] [Related]
10. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
11. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
13. Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer.
Qiao H; Lv R; Pang Y; Yao Z; Zhou X; Zhu W; Zhou W
Anal Cell Pathol (Amst); 2022; 2022():5259187. PubMed ID: 35425695
[TBL] [Abstract][Full Text] [Related]
14. Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction.
Sun Y; Yang M; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1379. PubMed ID: 36660642
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis/ferroptosis-related gene signature is correlated with immune infiltration and predict the prognosis for patients with breast cancer.
Li J; Zhang W; Ma X; Wei Y; Zhou F; Li J; Zhang C; Yang Z
Front Pharmacol; 2023; 14():1192434. PubMed ID: 37521466
[No Abstract] [Full Text] [Related]
17. Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer.
Wu Q; Zheng S; Lin N; Xie X
BMC Med Genomics; 2023 Apr; 16(1):87. PubMed ID: 37098532
[TBL] [Abstract][Full Text] [Related]
18. Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation.
Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N
Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491
[TBL] [Abstract][Full Text] [Related]
19. CD1C is associated with breast cancer prognosis and immune infiltrates.
Chen X; Zhang J; Lei X; Yang L; Li W; Zheng L; Zhang S; Ding Y; Shi J; Zhang L; Li J; Tang T; Jia W
BMC Cancer; 2023 Feb; 23(1):129. PubMed ID: 36755259
[TBL] [Abstract][Full Text] [Related]
20. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]